iCAD’s “ProFound Insights, ProFound Impact” Webinar Series to Feature Cleveland Clinic
12 Julho 2023 - 9:00AM
iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today
announced its “ProFound Insights, ProFound Impact” webinar series
will feature Dr. Laura Dean, a renowned breast radiologist at the
Cleveland Clinic. Titled “How Cleveland Clinic is Finding the
Breast Cancers Radiologists Fear the Most,” the live event will
take place on Thursday, July 20 at 10 am ET. The event will be
moderated by iCAD’s President and CEO, Dana Brown. To register,
visit this link.
"iCAD’s Breast AI Suite is revolutionizing breast cancer
screening. Our cutting-edge technology not only elevates the skills
of the nation's top radiologists but also reinforces their
excellence,” commented Dana Brown, President and CEO of iCAD, Inc.
“We look forward to showcasing Dr. Dean in this compelling event,
where she will provide valuable insights from her clinical
experience, share best practices, and present compelling case
studies that highlight the distinctive workflow advantages and
unique value our technologies offer to clinicians, facilities, and
patients.”
During the event, Dr. Dean will discuss how she leverages iCAD’s
market-leading technology to detect breast cancers, including
small, subtle tumors – the types of cancers radiologists fear the
most. She will also present a live clinical case review showcasing
how ProFound AI® can enhance cancer detection in a clinical
setting.
"Even for experienced radiologists, some findings are so subtle
they can be difficult to detect,” said Dr. Dean. “ProFound AI acts
as an extra set of eyes that empowers our team to catch even the
smallest, most difficult-to-detect cancers – and with greater
accuracy than ever. This reliable, game-changing technology not
only improves our confidence, it optimizes efficiency and improves
patient outcomes."
ProFound AI became the first technology of its kind to be FDA
cleared in 2018. Built with the latest in deep-learning artificial
intelligence, ProFound AI is clinically proven to improve
radiologists’ sensitivity by 8%, reduce the rate of false positives
and unnecessary callbacks by 7%, and slash reading time by more
than half.1
Launched last year, the “ProFound Insights, ProFound Impact”
webinar series has featured a number of esteemed clinical, IT, and
administrative experts, along with customer success stories and
impactful case studies from healthcare facilities around the globe.
Previous event recordings are available on the Company’s website,
www.icadmed.com.
About iCAD, Inc.Headquartered in Nashua, NH,
iCAD® is a global medical technology leader providing innovative
cancer detection and therapy solutions. For more information, visit
www.icadmed.com.
Forward-Looking StatementsCertain statements
contained in this News Release constitute “forward-looking
statements” within the meaning of the Private Securities Litigation
Reform Act of 1995, including statements about the expansion of
access to the Company’s products, improvement of performance,
acceleration of adoption, expected benefits of ProFound AI®, the
benefits of the Company’s products, and future prospects for the
Company’s technology platforms and products. Such forward-looking
statements involve a number of known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance, or achievements of the Company to be materially
different from any future results, performance, or achievements
expressed or implied by such forward-looking statements. Such
factors include, but are not limited, to the Company’s ability to
achieve business and strategic objectives, the willingness of
patients to undergo mammography screening in light of risks of
potential exposure to Covid-19, whether mammography screening will
be treated as an essential procedure, whether ProFound AI will
improve reading efficiency, improve specificity and sensitivity,
reduce false positives and otherwise prove to be more beneficial
for patients and clinicians, the impact of supply and manufacturing
constraints or difficulties on our ability to fulfill our orders,
uncertainty of future sales levels, to defend itself in litigation
matters, protection of patents and other proprietary rights,
product market acceptance, possible technological obsolescence of
products, increased competition, government regulation, changes in
Medicare or other reimbursement policies, risks relating to our
existing and future debt obligations, competitive factors, the
effects of a decline in the economy or markets served by the
Company; and other risks detailed in the Company’s filings with the
Securities and Exchange Commission. The words “believe,”
“demonstrate,” “intend,” “expect,” “estimate,” “will,” “continue,”
“anticipate,” “likely,” “seek,” and similar expressions identify
forward-looking statements. Readers are cautioned not to place
undue reliance on those forward-looking statements, which speak
only as of the date the statement was made. The Company is under no
obligation to provide any updates to any information contained in
this release. For additional disclosure regarding these and other
risks faced by iCAD, please see the disclosure contained in our
public filings with the Securities and Exchange Commission,
available on the Investors section of our website at
http://www.icadmed.com and on the SEC’s website at
http://www.sec.gov.
Contact:
Media Inquiries:Jessica Burns, iCAD
+1-201-423-4492jburns@icadmed.com
Investor Inquiries:iCAD Investor Relationsir@icadmed.com
_______________1 Conant, E et al. (2019). Improving Accuracy and
Efficiency with Concurrent Use of Artificial Intelligence for
Digital Breast Tomosynthesis. Radiology: Artificial Intelligence. 1
(4). Accessed via
https://pubs.rsna.org/doi/10.1148/ryai.2019180096
Icad (NASDAQ:ICAD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Icad (NASDAQ:ICAD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024